After indefinitely suspending their plans over a Chinese regulatory snag, Sony and Olympus are finally kicking off their long-planned medical device joint venture, planning to sell endoscopes and imaging technologies around the world.
Sony and Olympus in Japan are putting off indefinitely their highly touted partnership to concoct new endoscopes and other medical devices. The delay stems from continued Chinese regulatory snafus.
Panasonic may sell its successful healthcare/medical device business to raise some badly needed money in the face of struggling plasma TV and consumer electronics sales. The price tag: $1.05 billion, according to at least two media accounts.
EndoChoice's drive to develop a better gastrointestinal endoscopic tool has led to a merger with an Israeli startup and a $45 million round of financing to back the deal and fuel future expansion.
Sony and Olympus made headlines in September when they announced plans to partner and develop medical devices, but those ambitions will have to wait for next year as the two face a delay over anti-trust sign-offs.
Barely two weeks after Sony solidified plans to expand its medical device and equipment business, Moody's Investor Service lowered its credit rating by a notch.
It turns out that Sony's ($SNE) bid to expand its focus into medical equipment isn't necessarily well received by investors at the struggling Japanese consumer electronic giant.
Sony ($SNE) and Olympus ($OCPNY) will partner to develop and make new endoscopes and other medical devices, the companies disclosed today.
Months after announcing plans to seek a serious capital infusion, Japan's Olympus ($OCPNY) appears to have chosen Sony as the suitor suited for the task.
Japan's Olympus ($OCPNY)--one of the world's biggest makers of endoscope equipment (as well as cameras)--appears close to inking a deal with Sony to gain a badly-needed capital infusion.